Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial
-
Published:2024-02
Issue:2
Volume:9
Page:102237
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Michels S.ORCID, Massutí B., Vasyliv I., Stratmann J., Frank J., Adams A., Felip E., Grohé C., Rodriguez-Abreu D.ORCID, Bischoff H., Carcereny i Costa E., Corral J., Pereira E., Fassunke J., Fischer R.N., Insa A., Koleczko S., Nogova L.ORCID, Reck M.ORCID, Reutter T., Riedel R., Schaufler D., Scheffler M.ORCID, Weisthoff M.ORCID, Provencio M., Merkelbach-Bruse S., Hellmich M.ORCID, Sebastian M.ORCID, Büttner R., Persigehl T.ORCID, Rosell R.ORCID, Wolf J.
|
|